What happened
Shares of Gracell Biotechnologies (NASDAQ:GRCL) were up 21.5% Tuesday afternoon. The healthcare stock rose for the second consecutive day, boosted by an analyst's upgrade, as well as by positive trial news. The stock is up more than 156% so far this year.
So what
Gracell is a clinical-stage biotech company that makes cell therapies to treat cancers and autoimmune diseases. Over the weekend, the company announced positive long-term follow-up trial data regarding its lead therapy, GC012F, to treat patients with relapsed/refractory B-cell non-Hodgkin's lymphoma. The CAR-T therapy is a CD19 and B-cell maturation antigen.
In the study, all nine patients showed an overall response rate nine months after the therapy, with 77.8% having a complete response (CR) rate at three months and 66.7% having a CR at six months. The study comes on the heels of an announcement on June 3 that said GC012F did well in long-term follow-ups as a therapy to treat relapsed/refractory multiple myeloma.
In likely responses to the trial data, BTIG analyst Justin Zelin reiterated his buy rating on the stock with a price target of $20, and analyst Joseph Catanzaro from Piper Sandler maintained his buy rating on Gracell, with a price target of $10.
Now what
The company's pipeline has 12 programs, including six potential indications for GC012F. That the therapy has shown a strong safety profile, as well as long-term efficacy, is a big deal, but it is still in early-stage trials.
It's also worth noting that the small patient population size -- only nine participants -- means it may be difficult replicating GC012F's results in a larger relapsed/refractory B-cell non-Hodgkin's lymphoma patient group.
The company had, as of the first quarter, $186 million in cash, enough to probably finance operations into 2026.
10 stocks we like better than Gracell Biotechnologies
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Gracell Biotechnologies wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of June 12, 2023
Jim Halley has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
